Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension.
|
31514181 |
2020 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 has been studied as a predictor of and prognostic marker in coronary artery disease, myocardial infarction, and heart failure.
|
30765295 |
2020 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Lower risk for heart failure with higher ET1 levels could not be clearly shown in a model including health behaviors.
|
31515065 |
2020 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting the EC-Foxp1-TGF-β1-endothelin-1 pathway might provide a future novel therapy for heart failure.
|
31177814 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results revealed that TCDD directly induces cardiotoxicity in the postnatal period represented by progressive hypertrophy in which ANP, β-MHC, and ET-1 have potentials to mediate the cardiac hypertrophy and heart failure.
|
31270306 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum concentration of big endothelin-1 (ET-1) has prognostic significance in heart failure.
|
29913121 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Concentrations of ET-1 above the median were associated with shorter time to incident HF, MI, cardiovascular mortality, all-cause mortality, and the composite of incident HF/MI/cardiovascular mortality (all log-rank <i>P</i> < 0.001).
|
30213784 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The actions of ET-1 are evident during normal adaptive physiological responses and increased under pathophysiological conditions, such as following myocardial infarction and during heart failure, where ET-1 levels are elevated.
|
29470978 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 (ET-1) and its receptor endothelin A receptor (ET[Formula: see text] have been shown to be upregulated in a high glucose environment, which increase the incidence of diabetes-related heart failure.
|
30149760 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac hypertrophy, induced by neurohumoral factors, including angiotensin II and endothelin-1, is a major predisposing factor for heart failure.
|
29872396 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevated ET-1 was associated with worse HF, lower right ventricular function, higher pulmonary pressure, and higher left atrial volume index despite similar left ventricular function.
|
28398455 |
2017 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our meta-analysis provided evidence that increased plasma levels of ET-1, big ET-1, and CT-proET-1 were associated with poor prognosis or mortality for HF populations.
|
29390406 |
2017 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, elevated natriuretic peptides, ST2, endothelin-1, mid-regional-pro-adrenomedullin, copeptin, and galectin-3 have all been well validated to predict death and heart failure following a MI and provide risk stratification information for heart failure.
|
28491088 |
2017 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our study shows that fenofibrate may protect against ET-1-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiac hypertrophy and heart failure.
|
27629528 |
2017 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The increased EDN1 production may lead to constriction of coronary arteries, reducing coronary blood flow which may in turn increase the load on left ventricle, impairing contractility of the heart resulting in a DCM phenotype, an end stage of heart failure.
|
25042451 |
2014 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevated atrial ET-1 content is associated with increased LA size, AF rhythm, hypertension, and heart failure.
|
20495015 |
2010 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A common endothelin-1 gene haplotype may be a pharmacogenetic predictor of a favorable clinical response to beta-blocker therapy in heart failure patients.
|
18953265 |
2009 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Despite this baseline cytosolic HDAC5 shift, endothelin-1 produced more rapid HDAC5-GFP nuclear export in HF versus control myocytes.
|
18218981 |
2008 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).
|
16762801 |
2006 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Experimental studies and clinical trials have demonstrated that ET-1 plays a major role in normal cardiovascular homeostasis and in the functional and structural changes observed in arterial and pulmonary hypertension, glomerulosclerosis, atherosclerosis, and heart failure.
|
16855133 |
2006 |
Heart failure
|
0.600 |
Biomarker
|
disease |
LHGDN |
Differential role of TGF-beta1/bFGF and ET-1 in graft fibrosis in heart failure patients.
|
16095497 |
2005 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
16360360 |
2005 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These are the first data to demonstrate that cardiac overexpression of ET-1 is sufficient to cause increased expression of inflammatory cytokines and an inflammatory cardiomyopathy leading to heart failure and death.
|
14718401 |
2004 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 (ET-1) is considered to be involved in the development and progression of heart failure.
|
12193094 |
2002 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevation of ventricular filling pressure up-regulates RLX expression and the hormone acts as a potent inhibitor of endothelin 1, the most powerful vasoconstrictor in heart failure.
|
11641245 |
2001 |